A new blood test used in combination with a conventional prostate-specific antigen (PSA) screening sharply increases the accuracy of prostate cancer diagnosis, and could eliminate tens of thousands of unneeded, painful, and costly prostate biopsies annually, according to a study led by researchers at Dana-Farber Cancer Institute.

The majority of men who receive one of the standard treatments for localized prostate cancer - surgery or radiation therapy - have an excellent outcome.

Restricting carbohydrates, regardless of weight loss, appears to slow the growth of prostate tumors, according to an animal study being published this week by researchers in the Duke Prostate Center.

Fox Chase Cancer Center researchers have discovered that low-oxygen regions in prostate tumors can be used to predict a rise in prostate-specific antigen (PSA) levels, a marker of tumor recurrence in prostate cancer. The long-term study results will be presented at the 2009 American Society of Clinical Oncology annual meeting in Orlando, FL.

Fox Chase Cancer Center researchers have identified a genetic marker that is associated with an earlier onset of prostate cancer in Caucasian men who have a family history of prostate cancer. If the data are confirmed, the marker may help clinicians personalize prostate cancer screening.

For men younger than 50 with prostate cancer, undergoing a radical prostatectomy can greatly increase their chances for long-term survival, according to a new study from Henry Ford Hospital.

Prostate cancer patients who undergo therapy to decrease testosterone levels increase their risk of developing bone- and heart-related side effects compared to patients who do not take these medications, according to a new analysis.

Johns Hopkins researchers have developed a new technique that may improve robotic prostate surgery by using a second robot for taking three-dimensional ultrasound images of the prostate and surrounding structures during the procedure.

One of the few research projects to study the spread of prostate cancer to the bones using three-dimensional models of tissue-engineered bone is underway at QUT's Institute of Health and Biomedical Innovation (IHBI).

In patients with prostate cancer undergoing prostatectomy, MR imaging plays an important role in determining if the cancer is restricted to the prostate gland or if it has spread beyond the capsule, according to a study performed at the University of California, Los Angeles, Los Angeles, CA.

One cell…one initial set of genetic changes – that’s all it takes to begin a series of events that lead to metastatic cancer. Now, Johns Hopkins experts have tracked how the cancer process began in 33 men with prostate cancer who died of the disease. Culling information from autopsies, their study points to a set of genetic defects in a single cell that are different for each person’s cancer.

On Tuesday Dendreon (DNDN) announced positive results in a trial of Provenge in men with advanced prostate cancer. The trial, according to their press release, "met its primary endpoint of improving overall survival compared to a placebo control."